Sun Pharmaceutical vs Lupin: share price, P/E, ROE and financials compared
Sun Pharmaceutical Industries
Lupin
Sun Pharmaceutical and Lupin at a glance
Sun Pharmaceutical and Lupin are both listed in Healthcare. Sun Pharmaceutical is the larger by market cap, at ₹4.5L Cr against ₹90,914 Cr for Lupin (4.9 times as large). On valuation, Lupin has the lower P/E (17.5× against 40.7×) and the lower price-to-book (3.78× against 4.99×). On returns and margins, Lupin has the higher ROCE (28.3% against 17.9%) and the higher ROE (23.9% against 13.1%). Over three years, Lupin has faster 3-year sales growth (+19.1% against +10.4% a year) and faster 3-year profit growth (+131.4% against +10.6% a year). Sun Pharmaceutical carries less debt for its equity, with a debt-to-equity of 0.04× against 0.26×.
Key metrics, side by side
| Metric | Sun PharmaceuticalSUNPHARMA | LupinLUPIN |
|---|---|---|
| Price (₹) | 1,860.00 | 1,988.10 |
| Market cap (₹ Cr) | 4,46,276 | 90,914 |
| P/E | 40.7× | 17.5× (the lower figure, shaded) |
| P/B | 4.99× | 3.78× (the lower figure, shaded) |
| Dividend yield, trailing | 0.86% | 0.91% |
| ROE | 13.1% | 23.9% (the higher figure, shaded) |
| ROCE | 17.9% | 28.3% (the higher figure, shaded) |
| Operating margin (OPM) | 28.2% | 28.9% |
| Net margin (NPM) | 17.8% (the higher figure, shaded) | 16.9% |
| Sales CAGR 3Y | +10.4% | +19.1% (the higher figure, shaded) |
| Profit CAGR 3Y | +10.6% | +131.4% (the higher figure, shaded) |
| Debt to equity | 0.04× (the lower figure, shaded) | 0.26× |
| Interest cover | 45.6× (the higher figure, shaded) | 17.7× |
| Net profit TTM (₹ Cr) | 10,966 | 5,206 |
| 1Y return | +8.2% (the higher figure, shaded) | −0.5% |
| Promoter holding | 52.68% | 46.84% |
Sun Pharmaceutical vs Lupin: common questions
Which is bigger, Sun Pharmaceutical or Lupin?
By market cap, Sun Pharmaceutical is bigger at ₹4.5L Cr, against ₹90,914 Cr for Lupin (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹10,966 Cr for Sun Pharmaceutical and ₹5,206 Cr for Lupin.
Which has a lower P/E ratio, Sun Pharmaceutical or Lupin?
Sun Pharmaceutical trades at a P/E of 40.7× and Lupin at 17.5×. Lupin has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Sun Pharmaceutical or Lupin?
Sun Pharmaceutical reports a return on equity of 13.1% and Lupin 23.9%. Lupin has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Sun Pharmaceutical or Lupin?
Over the last three years: Sales grew +10.4% a year at Sun Pharmaceutical and +19.1% at Lupin, so Lupin grew sales faster; profit grew +10.6% a year at Sun Pharmaceutical and +131.4% at Lupin, so Lupin grew profit faster. Past growth doesn’t predict future growth.